We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Genentech’s Perjeta For HER2-Positive Breast Cancer
FDA Approves Genentech’s Perjeta For HER2-Positive Breast Cancer
June 15, 2012
The FDA has approved Roche subsidiary Genentech’s Perjeta as part of a first-line treatment combination for patients with HER2-positive metastatic breast cancer.